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Abstract
Background: Although the necessity of divalent magnesium and manganese for full activity of
sugar nucleotidyltransferases and glycosyltransferases is well known, the role of these metal cations
in binding the substrates (uridine 5'-triphosphate, glucose-1-phosphate, N-acetylglucosamine-1-
phosphate, and uridine 5'-diphosphate glucose), products (uridine 5'-diphosphate glucose, uridine
5'-diphosphate N-acetylglucosamine, pyrophosphate, and uridine 5'-diphosphate), and/or enzyme is
not clearly understood.
Results: Using isothermal titration calorimetry we have studied the binding relationship between
the divalent metals, magnesium and manganese, and uridine 5'-phosphates to determine the role
these metals play in carbohydrate biosynthesis. It was determined from the isothermal titration
calorimetry (ITC) data that Mg+2 and Mn+2 are most tightly bound to PPi, Kb = 41,000 ± 2000 M-1
and 28,000 ± 50,000 M-1 respectively, and UTP, Kb = 14,300 ± 700 M-1 and 13,000 ± 2,000 M-1
respectively.
Conclusion:  Our results indicate that the formal charge state of the phosphate containing
substrates determine the binding strength. Divalent metal cations magnesium and manganese
showed similar trends in binding to the sugar substrates. Enthalpy of binding values were all
determined to be endothermic except for the PPi case. In addition, entropy of binding values were
all found to be positive. From this data, we discuss the role of magnesium and manganese in both
sugar nucleotidyltransferase and glycosyltransferase reactions, the differences in metal-bound
substrates expected under normal physiological metal concentrations and those of
hypomagnesaemia, and the implications for drug design.
Background
The roles that nucleotides play in cellular metabolism
range in scope from their use as enzyme substrates to reg-
ulators for numerous biochemical pathways. Because of
their biological importance and the requirement of diva-
lent metals for biological activity, the binding relationship
between various metals and nucleotides has been well
documented to shed light on the role of metal-nucleotide
complexes in the conformational changes that occur in
DNA biosynthesis [1-4] and the energy pathways that
involve ATP [5-12].
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Recent studies suggest that certain metabolic disorders are
linked to serum magnesium concentrations in a way that
can be partially explained by these relative metal-binding
equilibria. For example, individuals with hypomagnesae-
mia – reduced serum magnesium concentration – have an
increased incidence of metabolic disorders such as type 2
diabetes mellitus [13-20] and high blood pressure [13].
Simple oral administration of magnesium chloride can
increase serum magnesium concentrations and decrease
total cholesterol and HDL levels while increasing LDL and
insulin sensitivity in these patients [21-23]. In patients
with high cholesterol and hypomagnesaemia, magnesium
treatment is attributed to increasing the effectiveness of
statin pharmaceuticals by shifting the equilibrium to the
formation of a Mg+2-ATP complex which is a necessary
intermediate in the cholesterol biosynthetic pathway [24].
Surprisingly, searches for an explanation of the effect of
magnesium supplementation on insulin levels so far have
focused only on metal effects at the DNA level [1] and not
on the effects of metals on the relative amounts of the sub-
strates involved in glucose metabolism. Such discussions
are hindered by the lack of reports of the magnesium
binding affinities to these substrates.
The biochemical pathway that synthesizes glycogen and
degrades it (Scheme 1) plays an important role in cellular
function and metabolism. This pathway is responsible for
the storage of glucose and glycogen as well as the regula-
tion of blood glucose levels. For this reason glycogen syn-
thase as well as phosphorylase b  have been targets of
diabetic drug targets [25-28]. It has also been shown that
the biocatalyst that activates glucose as ADP-glucose in
plants plays a regulatory role in starch biosynthesis [29-
31] which tags all three biocatalysts as contributing to the
regulation of glucose concentrations.
Scheme 1: Biochemical pathway for the synthesis and degradation of 
glycogen. General classification and the specific names of biocatalysts 
associated with carbohydrate biosynthesis are shown.
While it is widely known that divalent cations, in particu-
lar Mg+2 and Mn+2, play a very important role in carbohy-
drate biocatalysis, the actual mechanism by which the
metal interacts with the ligand and the enzymes is not
clearly understood. This has important implications in
drug development; whether the cation generally binds
tightly to the protein active site or binds to the ligand
before ligand binding to the protein is an important con-
sideration in designing effective inhibitors of this interac-
tion. It is well documented that uridine triphosphate
(UTP), pyrophosphate (PPi), glucose-1-phosphate (Glc-1-
P), and uridine diphosphate glucose (UDP-Glc) all bind
and act as inhibitors [32-35], whereas uridine diphos-
phate (UDP) was demonstrated by Gillett and coworkers
[36] to not bind to UDP-Glc pyrophosphorylase. This
result is confusing since other researchers have deter-
mined UDP to be an inhibitor of UDP-Glc pyrophospho-
rylase [33,34]. This raises the question of how inhibitor
binding is related to inhibitory affect. Herein, we discuss
the binding of Mg+2 and Mn+2 with UTP, UDP, uridine
monophosphate (UMP), UDP-Glc, and PPi in order to
gain an understanding in how and why sugar nucleotidyl-
transferases and glycosyltransferases (type B) are metal
dependant, and to determine in what order metal binding
occurs (i.e. does the metal bind to the ligand or biocata-
lyst first) and what role that has on catalytic activity or
inhibition.
Results and discussion
While the binding of Mg+2 to nucleotide phosphates has
been studied previously [5,7,11], the binding relationship
between the metals, Mg+2 and Mn+2, and uridine phos-
phates have not been described. Because the primary
interaction between the metal and nucleotides occurs
between the phosphates and the metal one would expect
the binding parameters between ATP and UTP to be simi-
lar. It would also be expected that little binding would be
lost by the addition of glucose to UDP to form UDP-glu-
cose. To address these questions, we determined the ther-
modynamics of binding of Mg+2 and Mn+2 to UTP, UDP,
UMP, UDP-Glc, Glc-1-P, Glc, U, and PPi at the physiolog-
ically relevant temperature of 37°C using isothermal titra-
tion calorimetry (ITC) by the direct titration of a solution
of magnesium or manganese (II) chloride into a solution
containing the phosphate containing compound being
studied (Figure 1). It was determined from the ITC data
that Mg+2 and Mn+2 are most tightly bound to PPi, Kb =
41,000 ± 2000 M-1 and 28,000 ± 50,000 M-1 respectively,
and UTP, Kb = 14,300 ± 700 M-1 and 13,000 ± 2,000 M-
1respectively (Figure 2). The binding parameters deter-
mined for the binding of Mg+2 and Mn+2 to UDP and UMP
were found to be less than that of UTP. The degree of asso-
ciation between Mg+2 and Mn+2 decreases as phosphates
are removed (UTP > UDP > UMP). However, as expected,
the binding parameters measured were comparable to
previously reported results for the binding of Mg+2 to ATP,
ADP, AMP, and UMP [1,5-7]. In addition, as expected,
there was no measurable binding of Mg+2 and Mn+2 to glu-Chemistry Central Journal 2008, 2:15 http://journal.chemistrycentral.com/content/2/1/15
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cose and uridine which do not contain negatively charged
phosphates.
Comparison of the binding constants for the binding of
Mg+2 and Mn+2 to UDP-Glc to the binding of Mg+2 and
Mn+2 to UDP affords an approximately 10-fold decrease
in binding. This significant decrease in binding due to the
addition of glucose was not expected; UDP-Glc is often
drawn directly bound to these divalent metals. In contrast,
the binding values associated with the binding of Mg+2
and Mn+2 to Glc-1-P were found to be similar in strength
to the binding of Mg+2 and Mn+2 to UMP. This data sug-
gests that the binding of Mg+2 and Mn+2 to phosphates is
dependent on the binding environment of the phosphates
involved in the coordination of the metals, Mg+2 and
Mn+2. For comparison, binding affinities to N-acetylglu-
cosamine,  N-acetylglucosamine-1-phosphate, and urid-
ine 5'-diphosphate N-acetylglucosamine were also
measured. From the binding constants the following pat-
tern of affinities emerges: PPi > UTP > UDP > UMP ≈ UDP-
Glc ≈ Glc-1-P ≈ GlcNAc-1-P > UDP-GlcNAc. This data
demonstrates a great effect on metal affinities upon sub-
stitution at phosphate. If the phosphate has no substitu-
ents covalently bound, as in the case of PPi, the binding
constant is large. However, in the case of UMP, UDP-Glc,
and Glc-1-P, in which the substrate is bound directly to
the binding phosphate, the binding constant is signifi-
cantly smaller. Finally, in the examples of substrates not
having phosphate groups present, GlcNAc, Glc and U, the
binding of Mg+2 and Mn+2 to the substrates was so weak as
to preclude accurate binding affinity determinations,
which indicates the importance that the charged phos-
phates play in binding divalent metals.
Thermodynamic values for the titrations were determined
and for all cases, except for the titration of pyrophosphate
by Mg+2 and Mn+2, the binding enthalpies were endother-
mic. All titrations afforded a positive change in entropy,
which correlates to an increase in disorder caused by the
loss of a water shell around the metal and phosphate com-
pound as the metal coordinates to the phosphate com-
pound. This increase in disorder allowed the overall
coordination of Mg+2 and Mn+2 to the phosphate to be
thermodynamically allowed with the free energy follow-
ing a similar pattern as the binding values (PPi > UTP >
UDP > UMP ≈ UDP-Glc ≈ Glc-1-P ≈ GlcNAc-1-P > UDP-
GlcNAc).
Although Mg+2 and Mn+2 bind at very similar strengths to
phosphates, the intracellular concentrations of Mg+2 and
Mn+2 vary greatly. Although metal concentrations can vary
depending on cell state, type, and organelle, given intrac-
ellular concentrations of Mg+2 and Mn+2 of 1.5 nM [37]
and 10 nM [38] respectively, the amount of phosphate
expected to be bound to Mg+2 and Mn+2 varies greatly as
shown in Figure 3. At these physiological metal concentra-
tions, the concentration of Mn+2 is not large enough to
shift the equilibrium of binding in the direction of metal-
phosphate complex formation. However, all of the phos-
phates show a measurable degree of binding to Mg+2 at
intracellular concentrations of Mg+2. Uridine triphosphate
and PPi are almost completely bound (> 95%) to Mg+2 at
intracellular concentrations of Mg+2, while UDP is mostly
Binding constants of phosphates bound to Mg+2 (white) and  Mn+2 (gray) Figure 2
Binding constants of phosphates bound to Mg+2 (white) and 
Mn+2 (gray).
Thermogram (top) and binding isotherm (bottom) showing  the addition of 75 mM MgCl2 (syringe) into 2.1 mM UTP  (cell) in 100 mM HEPES at pH 7.6 and 37°C Figure 1
Thermogram (top) and binding isotherm (bottom) showing 
the addition of 75 mM MgCl2 (syringe) into 2.1 mM UTP 
(cell) in 100 mM HEPES at pH 7.6 and 37°C.Chemistry Central Journal 2008, 2:15 http://journal.chemistrycentral.com/content/2/1/15
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bound (83%), and UMP, UDP-Glc, and Glc-1-P are only
partially bound to Mg+2 (~ 25%).
When the concentration of magnesium decreases, as is the
case in hypomagnesaemia (0.7 mM Mg+2) there can be
significant changes in the phosphate-magnesium concen-
tration (Figure 4). In cases where Mg+2 is tightly bound,
PPi and UTP, there is not a large change in complex forma-
tion. However, when the binding is not as tight, as is the
case with UDP, UMP, UDP-Glc, Glc-1-P, GlcNAc-1-P, and
UDP-GlcNAc, the concentration of the phosphate-magne-
sium complex is greatly reduced by the change in magne-
sium ion concentration associated with hypomagnesaem
ia. This decrease in magnesium-phosphate complex for-
mation would be expected to lead to decreased activity of
glycogen synthase because of the role that AMP plays as an
allosteric activator as well as decreasing the activity of
phosphorylase b which is allosterically activated by glu-
cose-6-phosphate.
To understand the role that metal binding plays in enzy-
matic activity we analyzed several known crystal structures
of sugar NTs [39-49], GT-As [50-60] and GT-Bs [61-67].
The active site analysis of sugar NT crystal structures
revealed the metal ion, Mg+2, ligands to be one to two oxy-
gen atoms from the phosphates and two to three coordi-
nated oxygens from aspartic acid residues from the
enzyme in question [40,48]. Though not as complex, the
coordination of Mg+2 in sugar NTs is similar to the octahe-
dral coordination site of Mn+2 seen in GT-As, where the
active site analysis shows two of the coordinating atoms to
Mn+2 are oxygens from the α- and β- phosphates and three
to four coordination sites are direct interactions to the
enzyme [50,52-54], [56-60]. A well-defined metal coordi-
nation site in GT-As allows for a high degree of coordina-
tion to occur between the metal, Mn+2, and the protein;
this fact implies the presence of a permanent metal bind-
ing site [54]. This analysis coupled with the fact of a low
intracellular concentration of Mn+2 (10 nM) [38] makes
the presence of a permanent metal binding site appropri-
ate unless higher local metal concentrations can be main-
tained at the site of action of particular GTs. The enzymes
that constitute GT-Bs, which are not metal dependent,
have positively charged amino acid residues, four
arginines, which are able to form hydrogen bonds directly
to the phosphates [61-67].
Conclusion
Our findings of no manganese-phosphate complex for-
mation at physiological manganese ion concentration fits
previously reported crystal structure determinations dem-
onstrating the presence of a permanent binding site in GT-
As for manganese [54]. For highest activity at low manga-
nese concentration, the enzyme would need to have a way
to permanently sequester manganese for full biocatalytic
function. However for sugar NTs, which are magnesium
dependent, the need for a permanent binding site is not
required due to the much higher physiological concentra-
tion of divalent magnesium in healthy cells. As for inhib-
itors of sugar NTs, free UTP has been shown to be an
inhibitor of Mg-UTP [35], and explains why UDP is an
inhibitor in the presence of Mg+2 while it was found not to
bind to the enzyme in the absence of a divalent metal
[35].
Percent of phosphate bound to Mg+2 at a normal physiologi- cal Mg+2 concentration of 1.5 mM (white) and at a hypomag- nesaemia concentration of 0.7 mM (gray) Figure 4
Percent of phosphate bound to Mg+2 at a normal physiologi-
cal Mg+2 concentration of 1.5 mM (white) and at a hypomag-
nesaemia concentration of 0.7 mM (gray).
Percent of phosphate bound to Mg+2 (white) at the intracellu- lar concentration of 1.5 mM. No measurable binding is  observed for Mn+2 Figure 3
Percent of phosphate bound to Mg+2 (white) at the intracellu-
lar concentration of 1.5 mM. No measurable binding is 
observed for Mn+2.Chemistry Central Journal 2008, 2:15 http://journal.chemistrycentral.com/content/2/1/15
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The role magnesium plays in the formation of metal-
phosphate complexes may shed some light in why magne-
sium chloride therapy has lead to a decrease in serum glu-
cose levels in patients with type 2 diabetes [20-23]. With
the increase of the serum Mg+2 concentrations, there will
be an increase in the formation of magnesium-phosphate
complexes. The complexes formed play a critical role by
activating the biocatalysts involved in the manner in
which glucose is biochemically stored and released. The
decrease in biocatalyst function would not allow for the
biochemical pathway to function properly, adequately
sequestering glucose as glycogen when glucose levels are
high and degrading glycogen when glucose levels are low.
Obviously, these implications await human trials now
that the basic biochemical data is available.
Knowledge of the method in which the metal binds to the
substrate can also play an important role in drug design.
When contemplating inhibitor design for sugar NTs, one
must design the inhibitor such that it is able to compete
against the most prevalent form of the substrate, which for
this class of enzymes is the NTP-Mg+2 complex. According
to our results, the metal cation binds to NTP first and then
after the reaction it leaves bound to PPi. In contrast, in
designing inhibitors for glycosyltransferases, one needs to
account for the binding that occurs between the manga-
nese and the substrate because manganese is likely to be
permanently bound in the active site and important in the
catalytic activity of GT-As while not being important for
the catalytic activity of GT-Bs. This knowledge of metal
affinities therefore may aid in the development of drug
candidates that are able to selectively inhibit one class of
glycosyltransferases and phosphorylases over another and
ultimately also may lead to diabetic drug development
[25-28].
Experimental
2-[4-(2-hydroxyethyl)-1-piperazinyl]-ethanesulfonic acid
(Hepes), tetrasodium pyrophosphate decahydrate, mag-
nesium chloride, and manganese (II) chloride were all
purchased from Fischer Scientific Company (Hanover
Park, IL). All other compounds were purchased from
Sigma Chemical Co. (St. Louis, MO) unless otherwise
noted and used without further purification. Nanopure
water (18.1 MHz) prepared from a Barnstead E-pure water
purification system was employed throughout.
Isothermal titration calorimetry
ITC experiments were performed on a Microcal VP-ITC
microcalorimeter (Northampton, MA) which was cali-
brated using the built-in electrical calibration check. All
ITC experiments were conducted in 100 mM Hepes buffer
pH 7.5 at 37°C. Nucleotide phosphate concentration was
determined spectrophotometrically from UV absorbance
measurements at 262 nm using an extinction coefficient
of ε262 = 20,000 cm-1 M-1 [68]. Glucose-1-phosphate con-
centrations were determined via electrospray ionization
mass spectrometry (ESI-MS) [69]. All solutions were
degassed immediately prior to use. Titrant solution (2.5,
7.5, or 10 μL) was added from a 300 μL microsyringe at an
interval of 200 sec. into the stirred sample cell (1.4288
mL) containing the nucleotide phosphate at a stirring rate
of 480 rpm. To correct for heats of dilution, control exper-
iments were performed by making identical injections of
the titrant solution into a cell containing only buffer and
these values were subtracted from the titration of the
titrant solution into the reaction cell. The titrant solution
contained the metal, Mg+2 or Mn+2 (75 mM), in Hepes
buffer (100 mM, pH 7.5). The reaction cell contained 2.5
– 7.5 mM substrate (UTP, UDP, UMP, UDP-Glc, Glc-1-P,
Glc, U, or PPi) in Hepes buffer (100 mM, pH 7.5). Data
was analyzed using nonlinear least-squares curve fitting in
Origin (7.0, OriginLab Corp., Northampton, MA) using
the standard one binding site model supplied by Origin.
This analysis yielded the thermodynamic parameters K
(binding constant), enthalpy of binding (ΔH), entropy of
binding (ΔS), and n, where n is the ratio of the metal ion
to the substrate in the complex. See Additional file 1 for
Isothermal titration calorimetry plots and tables contain-
ing n, K, ΔG, ΔH, and ΔS metal binding information for all
substrates and metals and their thermograms.
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